Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioids And The Limits Of FDA Power

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA adds a MedGuide for immediate-release opioids and shrinks their indication; the products seemed destined for an educational REMS, but is there even more the agency could do?


Related Content

Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review
Califf Sets Exit At FDA, Ostroff Could Return To Acting Commissioner Post
US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure
FDA's Latest Opioid Move Aims To 'Reset The Conversation' On Benzodiazepine Combo
Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts